ANTI-INFLAMMATORY ACTIVITY AND COX-1 RECEPTOR COMPETITION IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION TREATED WITH NONSELECTIVE COX-INHIBITOR AND LOW-DOSE ASPIRIN  by Lomakin, Nikita & Gruzdev, Alexie K.
E951
JACC April 5, 2011
Volume 57, Issue 14
  MYOCARDIAL ISCHEMIA AND INFARCTION 
ANTI-INFLAMMATORY ACTIVITY AND COX-1 RECEPTOR COMPETITION IN PATIENTS WITH ACUTE 
CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION TREATED WITH NONSELECTIVE COX-
INHIBITOR AND LOW-DOSE ASPIRIN
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Acute Myocardial Infarction -- Antiplatelet Therapies
Abstract Category: 3. Acute Myocardial Infarction—Therapy
Session-Poster Board Number: 1005-320
Authors: Nikita Lomakin, Alexie K. Gruzdev, Central Clinical Hospital of Presidential Department of Russian Federation, Moscow, Russian Federation
There are a lot of controversial information about nonsteroidal anti-inflammatory drugs (NSAID) cardiosafety. It is still unclear do NSAIDs develop 
cardioprotective or cardiotoxic effects. Also there is some evidence that there could be a COX-1 receptor binding competition between low-dose 
aspirin and nonselective COX-inhibitors if taking together. And that could be one of the possible explanations of cardiotoxic effects of COX-inhibitors. 
The aim of the study was to check this theory and to investigate the safety and efficacy of Lornoxicam, nonselective COX-inhibitor, in patients with 
acute coronary syndrome without ST-segment elevation (NSTEACS) and to evaluate the influence of Lornoxicam on the inflammatory markers.
Methods:  Overall 85 patients with NSTEACS were randomized to the prospective single-blind trial to receive lornoxicam (8/12mg/day) and aspirin 
(100mg/day) together or aspirin (100mg/day) alone for 15 days.
Results:  According to the six months follow-up results there were a significant reduction of the primary end point (myocardial infarction+ 
cardiovascular (CV) death+ unstable angina) in patients receiving lornoxicam compare with placebo (8,5% versus 33.3%, OR=0,18 ( 0,08-0,72 95% 
CI), P=0.006). CRP, IL-6 and IL-10 blood samples were drawn prior to randomization, and after 15 days of the treatment . CRP and IL-6 levels in 
the lornoxicam group were lower at 15 day compare to placebo (p < 0.01 for CRP , p=0,15 for IL-6). The anti-inflammatory cytokine IL-10 level was 
significantly higher at 15 day in lornoxicam group compare with placebo (p=0,04). No adverse events associated with lornoxicam were observed. At 
the same time there was a 38% significant increase in the thromboxane B2 level at 15 day in lornoxicam group compare with the decrease (60%) in 
the aspirin treated group (p=0,04).
Conclusion: Administration of lornoxicam along with aspirin was associated with significant reduction in CV outcomes in NSTEACS patients. 
Nevertheless there is a proven COX-1 receptor competition between aspirin and lornoxicam with the significant trend to thromboxane-A2 increase if 
taking aspirin and NSAID together. Additional larger trials are required to confirm the findings of this study
